EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients Treated With Radiotherapy: A Systematic Review of Literature

Yasmin A Civil, Nora D Purcell, Ralph de Vries, Arlene L Oei, Victor L J L Thijssen, Tanja D de Gruijl, Berend J Slotman, Famke L Schneiders, H J G Desirée van den Bongard

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2025.07.005 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Yasmin A Civil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, Department of Radiation Oncology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam…. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High tumor-infiltrating lymphocytes (TILs) levels in triple-negative and HER2-positive breast cancer are associated with better survival outcomes, highlighting its potential as prognostic biomarkers. Radiotherapy can also trigger immune cell infiltration. This systematic review evaluates the prognostic value of TILs in radiotherapy-treated breast cancer patients. A literature search (in PubMed, Embase and Web of Science) was performed up to April 5, 2024 (PROSPERO registration CRD42024401741). Two independent reviewers screened articles according to predefined criteria, resolving discrepancies through consensus. The collected outcomes were prognostic value of TILs for ipsilateral breast tumor recurrence (IBTR), any recurrence, distant metastasis (DM), overall survival (OS) and disease-free survival (DFS). Of 10,927 records, 11 studies (3899 patients) were included. Patients underwent lumpectomy or mastectomy, with or without postoperative radiotherapy. Three studies examined neoadjuvant partial breast irradiation. The stroma threshold for high vs. low TILs ranged from 5 to 50%, with most patients (73%) having low TILs. Low TILs patients significantly benefited from radiotherapy in reducing IBTR and any recurrence. In luminal B, triple-negative and HER2-positive subtypes, high TILs were associated with better outcomes in DM, OS and DFS. For radiotherapy-treated luminal A breast cancer, low TILs were associated with improved OS. For DCIS patients, low TILs correlated with reduced IBTR. TILs could be a prognostic biomarker for radiotherapy-treated breast cancer patients. However, study heterogeneity complicates comparisons. To refine personalized treatment, further prospective studies are necessary to investigate TILs levels and the impact of neoadjuvant radiotherapy on oncological outcomes across different breast cancer subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingBreast NeoplasmsNeoplasm Recurrence, LocalHumansFemalePrognosisRadiotherapy, AdjuvantNeoadjuvant TherapyDisease-Free SurvivalBiomarkers, TumorMastectomy

Stichwörter der Autor:innen

Personalized medicinePrognostic biomarkerRecurrenceSurvivalTumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Amsterdam UMC, Department of Radiation Oncology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands. Electronic address: y.civil@amsterdamumc.nl.
  • Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Medical Library, Vrije Universiteit, Amsterdam, The Netherlands.
  • Amsterdam UMC, Department of Radiation Oncology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands; Laboratory for Experimental Oncology and Radiobiology, Ams…
  • Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands; Center for Experimental Molecular Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands; Department of M…
  • Amsterdam UMC, Department of Radiation Oncology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.

Zitieren

APA

Civil, Y. A., Purcell, N. D., de Vries, R., Oei, A. L., Thijssen, V. L. J. L., de Gruijl, T. D., Slotman, B. J., Schneiders, F. L., & van den Bongard, H. J. G. D. (2026). Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients Treated With Radiotherapy: A Systematic Review of Literature. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.07.005

Vancouver

Civil YA, Purcell ND, de Vries R, Oei AL, Thijssen VLJL, de Gruijl TD, et al. Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients Treated With Radiotherapy: A Systematic Review of Literature. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.07.005

BibTeX
@article{Civil2026,
  author = {Civil, Yasmin A and Purcell, Nora D and de Vries, Ralph and Oei, Arlene L and Thijssen, Victor L J L and de Gruijl, Tanja D and Slotman, Berend J and Schneiders, Famke L and van den Bongard, H J G Desirée},
  title = {Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer Patients Treated With Radiotherapy: A Systematic Review of Literature},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2025.07.005}
}
Kostenlos starten →